Jade Biosciences (JBIO) Stock Analysis

What Jade Biosciences does

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Key metrics

ETFs linked to JBIO

Broad-market and Healthcare sector ETFs an investor holding Jade Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how JBIO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Jade Biosciences?

Jade Biosciences trades under the ticker JBIO on NASDAQ.

Which exchange is JBIO listed on?

JBIO is listed on NASDAQ.

What sector does Jade Biosciences operate in?

Jade Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze JBIO in a portfolio?

PortView shows JBIO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.